Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
Holding CRMD?
Track your performance easily
CRMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.89 - $13.85
Previous Close$8.57
Volume2.46M
Average Volume (3M)1.19M
Market Cap
$538.21M
Enterprise Value$492.73M
Total Cash (Recent Filing)$46.03M
Total Debt (Recent Filing)$556.00K
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Apr 01, 2025EPS Estimate
$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding60,677,204
10 Day Avg. Volume935,550
30 Day Avg. Volume1,185,495
Standard Deviation0.24
R-Squared0.12
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)8.84
Price to Sales (P/S)43.89
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue40.18
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-10.44
Forecast
1Y Price Target
$16.33Price Target Upside90.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cormedix News
PremiumCompany Announcements
CorMedix Approves Key Governance and Incentive Changes
PremiumCompany Announcements
CorMedix Inc. Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDefenCath sales in 3Q24 were ~$11.5MM, ahead of the estimate of $9.4MM and consensus of $10.3MM.
Growth PotentialMore than 30% of dialysis patients are in a Kidney Care Choices model, suggesting a significant market opportunity for DefenCath.
Market PenetrationCorMedix has secured commercial supply agreements with four of the top five dialysis providers, indicating strong market penetration.
Bears Say
Earnings GuidanceThere is a lack of visibility on the timing of initial large dialysis operator orders, preventing more specific 4Q sales guidance.
Market SentimentThe stock is down ~25% and this is viewed as unwarranted, presenting a compelling buying opportunity.
Stock PerformanceCRMD shares are under pressure partly due to consolidation after a significant move since mid-August and disappointment with lack of 4Q guidance.
---
Ownership Overview
1.50% Insiders
8.13% Mutual Funds
7.09% Other Institutional Investors
74.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $2.89 and its highest was $13.85 in the past 12 months.
What is Cormedix’s market cap?
Currently, no data Available
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Apr 01, 2025 which is in 101 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Oct 30, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.122 by $0.072.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is $0.03.
How many shares outstanding does Cormedix have?
Cormedix has 60,677,204 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.122. Following the earnings report the stock price went down -22.513%.
Which hedge fund is a major shareholder of Cormedix?
Among the largest hedge funds holding Cormedix’s share is Elliott Investment Management LP. It holds Cormedix’s shares valued at 13M.
---
Cormedix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.33 (90.55% Upside)
$16.33 (90.55% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
146.97%
12-Months-Change
Fundamentals
Return on Equity
-65.04%
Trailing 12-Months
Asset Growth
-15.14%
Trailing 12-Months
Company Description
Cormedix
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
---
CRMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call demonstrated strong revenue performance and market penetration of DefenCath, along with positive future EBITDA expectations. However, these positives are counterbalanced by increased operating expenses, potential revenue variability, and high customer concentration. Overall, the call reflects a cautiously optimistic outlook with significant achievements and some areas of concern.Read More>---
CRMD Stock 12 Month Forecast
Average Price Target
$16.33
▲(90.55% Upside)
Technical Analysis
Best Analysts Covering CRMD
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+45.59%
reiterated a buy rating 2 months ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +45.59% per trade.
---